Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete blindness with the progression of the disease. Some of patient-reported side effects include night visual impairment, loss of the visual field, and trouble in differentiating colors.
Download sample copy of this report at@ https://www.pharmaproff.com/request-sample/1249
The aim of diagnosing RP is to determine the type of mutation that has occurred in genes and can be detected by performing tests, including electroretinogram (ERG), visual field testing, and genetic testing.
According to the research findings, majority of the pipeline drug candidates are being developed for subretinal administration. It has been observed that this route of administration has high bioavailability and ensures direct effect on targeted cells.
Luxturna is the only approved therapy for the treatment of RP. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall RP therapeutic market is expected to rise significantly in the upcoming years.
Browse full report at@ https://www.pharmaproff.com/report/retinitis-pigmentosa-therapeutics-pipeline-analysis
Acucela Inc., HORAMA S.A., GenSight Biologics S.A., Novartis AG, Allergan Inc., Spark Therapeutics Inc., Sanofi-aventis Groupe, Ocugen Inc., Applied Genetic Technologies Corporation, Eyevensys, MeiraGTx Holdings plc, and Biogen Inc. are some of the key players involved in the development of drugs indicated for the treatment of RP.
US/Canada Toll-Free : +1-888-778-7886
International : +1-347-960-6455
Pharma Proff, a brainchild of Prescient & Strategic (P&S) Intelligence Private Limited, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments here
News-ID: 1956451 • Views: 1252
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
Hepatorenal Syndrome Therapeutics Pipeline Analysis 2018, Clinical Trials & Resu …
Hepatorenal syndrome (HRS) is a reversible functional renal impairment, that occurs in patients with advanced liver cirrhosis or those with fulminant hepatic failure. It is characterized by a marked reduction in glomerular filtration rate and renal plasma flow, in the absence of other causes of renal failure. Download the sample report at: https://www.pharmaproff.com/request-sample/1030 The symptoms of hepatorenal syndrome are fatigue, abdominal pain, malaise, ascites, jaundice, splenomegaly, and hepatomegaly. There are two
More Releases for Retinitis
Retinitis Pigmentosa (Retinitis) Industry Market Expected To Grow At High Cagr D …
Overview Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance. Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017 Report Highlights The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive
Market Research Focuses on Retinitis Pigmentosa (Retinitis) Market Pipeline Revi …
"The Report Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape. Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision
Retinitis Pigmentosa (RP) Market - Competitive Analysis and Forecast 2017-2025
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. As of now, there are no specific treatments available
Global Cytomegalovirus Retinitis Market Size, Share | MarketResearchReports.biz
Latest industry research report on: Global Cytomegalovirus Retinitis Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides
Retinitis Pigmentosa (Retinitis) Pipeline Insight and Therapeutic Assessment Rev …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinitis Pigmentosa (Retinitis). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Retinitis Pigmentosa (Retinitis) by development stage, therapy
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017" to its huge collection of research reports. Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance. Request Free